NICE
NICE recommends six drugs in final guidance
January 27, 2016Research and Development, Sales and Marketing NHS, NICE
NICE has published final recommendations approving drug treatments for ovarian cancer, prostate cancer, multiple myeloma, gastric cancer and idiopathic pulmonary …
NICE backs biosimilars with arthritis drug endorsements
January 27, 2016Research and Development, Sales and Marketing DMARDs, NICE, biosimilars, rheumatoid arthritis
NICE has published updated final guidance recommending seven biological disease modifying drugs (DMARDs) for treatment of severe rheumatoid arthritis which …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
A brighter future for the Cancer Drugs Fund?
January 14, 2016Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK
In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …
NICE recommends Velcade for MCL, and three diabetes drugs
December 23, 2015Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl
NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
NICE says no to NHS funding for Kadcyla
December 16, 2015Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer
NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
NICE turns down bone disorder drug for NHS
December 3, 2015Research and Development Alexion, NICE, Strensiq
NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
Personalised care key to diabetes management, says NICE
December 2, 2015Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes
UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …
Companies face mixed fortunes in ultra-orphan approvals
November 26, 2015Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs
UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …
Latest content
FibroFind appoints Lee Borthwick as CEO
